Giá hiện tại
Giá mục tiêu
Đánh giá của nhà phân tích
2 xếp hạng: Mua
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company is headquartered in Stockholm, Sweden.
e.g. Promoter holding
Loading chart...
Dự báo EPS và doanh thu theo đồng thuận của các nhà phân tích.
| Metric (B) | FY 2026 | FY 2026 | FY 2026 | FY 2027 | FY 2027 |
|---|---|---|---|---|---|
| $-0.41 | $-0.42 | $-1.65 | — | $-1.73 | |
| 0 | 0 | 0.01 | 0 | 0.04 | |
| — | — | — | — | — |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | EEvommune I... | EVMN | $315.50M | — | 1.26 | — | — | -69.50% | — |
| 2. | AAgomAb The... | AGMB | $313.22M | — | 1.07 | — | — | -39.20% | — |
| 3. | AArtiva Bio... | ARTV | $198.22M | — | 0.62 | — | — | -43.60% | -100.00% |
| 4. | SSionna The... | SION | $150.63M | — | 0.63 | — | — | -39.00% | — |
| 5. | KKyverna Th... | KYTX | $319.27M | — | 2.40 | — | — | -110.70% | — |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Quarter (M) | Dec 24 | Mar 25 | Jun 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|
Revenue | 5.1 | 0.89 | 1.75 | 0.42 | 0.6 | 2.21 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 5.1 | 0.89 | 1.75 | 0.42 | 0.6 | 2.21 |
Gross Profit % | 100% | 100% | 100% | 100% | 100% | 100% |
| 99.19 | 92.44 | 112.92 | 134.13 | 124.45 | 152.32 | |
EBIT | -94.09 | -91.55 | -111.17 | -133.71 | -123.84 | -150.1 |
OPM % | -1843.8% | -10262.89% | -6367.18% | -31910.98% | -20572.26% | -6782.83% |
Non-Operating Income | 10.01 | -19.99 | -4.19 | -3.4 | 15.31 | 7.43 |
PBT | -84.08 | -111.53 | -115.36 | -137.1 | -108.53 | -142.67 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - |
Net Income | -84.08 | -111.53 | -115.36 | -137.1 | -108.62 | -142.84 |
NPM % | -1647.56% | -12503.92% | -6607.27% | -32721.48% | -18042.52% | -6454.77% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
Revenue | 0 | 0 | 109.35 | 3.82 |
COGS | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 109.35 | 3.82 |
Gross Profit % | - | - | 100% | 100% |
| 287.49 | 320.89 | 299.71 | 458.26 | |
EBIT | -287.49 | -320.89 | -190.36 | -454.44 |
OPM % | - | - | -174.09% | -11905.82% |
Non-Operating Income | -1.31 | 9.56 | 21.47 | -23.03 |
PBT | -288.81 | -311.33 | -168.89 | -477.47 |
Income Tax | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - |
Net Income | -288.42 | -310.94 | -168.63 | -477.47 |
NPM % | - | - | -154.22% | -12509.14% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| 256.8 | 333.62 | 1,156 | 578.15 | |
| 4.94 | 149.04 | 0 | 588.59 | |
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | |
| 76.26 | 15.18 | 39.57 | 51.9 | |
Total Assets | 338.01 | 497.84 | 1,195.57 | 1,218.64 |
| 0 | 0 | 0 | 0 | |
| 289.08 | 455.39 | 1,129.33 | 1,095.46 | |
| 0 | 0 | 0 | 0 | |
| 27.25 | 23 | 47.68 | 50.92 | |
| 21.68 | 19.45 | 18.57 | 72.25 | |
Total Liabilities | 338.01 | 497.84 | 1,195.57 | 1,218.64 |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| -299.92 | -249.58 | -164.95 | -375.74 | |
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | |
Net CFNet Cash Flow | -299.92 | -249.58 | -164.95 | -375.74 |
FCFFree Cash Flow | -302.92 | -249.58 | -164.95 | -375.74 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| - | -83.5% | -21.3% | -42.9% | |
| - | - | - | - | |
| 5.81 | 12.10 | 18.20 | 10.28 | |
| - | 0.00 | 0.13 | 0.00 | |
Cash Conversion | 1.04 | 0.80 | 0.98 | 0.79 |
Payout Ratio | - | - | - | - |
| - | - | - | -96.5% | |
| - | - | - | - | |
| - | - | - | - | |
| 1.00 | 4.00 | 5.00 | 2.00 | |
| - | - | - | -11.36 | |
| 0.00 | 0.00 | 50.00 | 50.00 | |
| - | - | -1.5% | -125.1% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Ai sở hữu Vicore Pharma Holding AB, theo hồ sơ SEC
Chưa có hồ sơ sở hữu SEC cho công ty này.
Hồ sơ SEC và bản ghi cuộc gọi kết quả kinh doanh của Vicore Pharma Holding AB
Chưa có hồ sơ SEC cho công ty này.
What recent news says about Vicore Pharma Holding AB, scored for sentiment.